NeuMoDx Molecular Revenue and Competitors
Estimated Revenue & Valuation
- NeuMoDx Molecular's estimated annual revenue is currently $22.1M per year.
- NeuMoDx Molecular received $20.0M in venture funding in May 2016. 0
- NeuMoDx Molecular's total funding is $66M.
Employee Data
- 00
NeuMoDx Molecular Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $25.4M | 101 | 3% | N/A | N/A |
#2 | $6.8M | 54 | 4% | N/A | N/A |
#3 | $17.1M | 58 | 0% | N/A | N/A |
#4 | $2.6M | 26 | 0% | N/A | N/A |
#5 | $75M | 271 | 6% | N/A | N/A |
#6 | $4.6M | 38 | 0% | N/A | N/A |
#7 | $24.8M | 79 | 0% | N/A | N/A |
#8 | $1M | 4 | 0% | N/A | N/A |
#9 | $24.6M | 70 | -31% | N/A | N/A |
#10 | $2.8M | 21 | 0% | N/A | N/A |
What Is NeuMoDx Molecular?
$66M
Total Funding
N/A
Number of Employees
$22.1M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
NeuMoDx Molecular News
Sales trends for QIAstat-Dx and NeuMoDx systems were in line with our full ... well balanced between life science and molecular diagnostics,...
The firm's molecular diagnostic revenues were up 28 percent year over year to ... and sales for NeuMoDx dropped 15 percent to $27 million,...
1.1.8.2.1.1 Lab-on-a-chip and Molecular Biology ... Cancer Therapy; QIAGEN NV Selects NeuMoDx Molecular, Inc for CE-IVD Assays Purchase ...
NEW YORK – NeuMoDx has filed a response with the District of ... by Becton Dickinson that the molecular diagnostics developer infringed on ...
Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top ...
Other Companies in Ann Arbor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $133.4M | 0 | N/A | $1.4M |
#2 | $7.6M | 0 | N/A | $12.4M |
#3 | $0.2M | 2 | N/A | N/A |
#4 | $15M | 3 | -25% | N/A |
#5 | $0.2M | 3 | N/A | N/A |
NeuMoDx Molecular Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-03-28 | $10.5M | Undisclosed | Article | |
| 2014-04-02 | $21.0M | B | Pfizer Ventures | Article |
| 2016-05-03 | $20.0M | Undisclosed | Article |